Nuveen Asset Management LLC Has $341,000 Stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)

Nuveen Asset Management LLC decreased its holdings in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 77.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,938 shares of the biopharmaceutical company's stock after selling 101,232 shares during the quarter. Nuveen Asset Management LLC owned 0.24% of Corbus Pharmaceuticals worth $341,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Orbimed Advisors LLC increased its stake in shares of Corbus Pharmaceuticals by 28.5% in the fourth quarter. Orbimed Advisors LLC now owns 1,172,287 shares of the biopharmaceutical company's stock valued at $13,833,000 after buying an additional 259,735 shares during the period. Millennium Management LLC increased its stake in shares of Corbus Pharmaceuticals by 215.0% in the fourth quarter. Millennium Management LLC now owns 386,653 shares of the biopharmaceutical company's stock valued at $4,563,000 after buying an additional 263,902 shares during the period. Deutsche Bank AG increased its stake in shares of Corbus Pharmaceuticals by 46.8% in the fourth quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company's stock valued at $97,000 after buying an additional 2,616 shares during the period. Bank of America Corp DE increased its position in Corbus Pharmaceuticals by 29.7% during the 4th quarter. Bank of America Corp DE now owns 31,475 shares of the biopharmaceutical company's stock valued at $371,000 after purchasing an additional 7,207 shares during the period. Finally, BNP Paribas Financial Markets acquired a new stake in Corbus Pharmaceuticals during the 4th quarter valued at approximately $323,000. Institutional investors and hedge funds own 64.64% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CRBP shares. B. Riley reissued a "buy" rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, May 7th. HC Wainwright decreased their target price on shares of Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Wedbush reissued an "outperform" rating and set a $51.00 target price on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 12th. Oppenheimer decreased their target price on shares of Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, William Blair began coverage on Corbus Pharmaceuticals in a report on Friday, February 28th. They set an "outperform" rating on the stock. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $50.88.

Corbus Pharmaceuticals Trading Up 3.9%

NASDAQ CRBP opened at $8.80 on Friday. The firm has a market capitalization of $107.69 million, a P/E ratio of -1.88 and a beta of 3.19. The business has a fifty day simple moving average of $6.79 and a 200 day simple moving average of $9.56. Corbus Pharmaceuticals Holdings, Inc. has a 12 month low of $4.64 and a 12 month high of $61.90.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.13). As a group, sell-side analysts predict that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 EPS for the current fiscal year.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

Want to see what other hedge funds are holding CRBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.